382 related articles for article (PubMed ID: 11964367)
1. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
2. Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
Gurewich V; Pannell R; Simmons-Byrd A; Sarmientos P; Liu JN; Badylak SF
J Thromb Haemost; 2006 Jul; 4(7):1559-65. PubMed ID: 16839354
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase.
Credo RB; Burke SE
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):8S-18S. PubMed ID: 8770836
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
5. Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.
Pannell R; Li S; Gurewich V
PLoS One; 2015; 10(3):e0122018. PubMed ID: 25811605
[TBL] [Abstract][Full Text] [Related]
6. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis.
Pannell R; Kung W; Gurewich V
J Thromb Haemost; 2007 May; 5(5):1047-54. PubMed ID: 17459007
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
[TBL] [Abstract][Full Text] [Related]
8. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
[TBL] [Abstract][Full Text] [Related]
9. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of Lys- and mini-plasminogen on clot lysis induced by recombinant urokinase and recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Davidson DJ; Lubbers NL; Reininger IM; Henkin J
Thromb Res; 1996 Sep; 83(6):421-31. PubMed ID: 8885137
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
12. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
14. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
16. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
17. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
[TBL] [Abstract][Full Text] [Related]
18. Superficial accumulation of plasminogen during plasma clot lysis.
Sakharov DV; Rijken DC
Circulation; 1995 Oct; 92(7):1883-90. PubMed ID: 7671373
[TBL] [Abstract][Full Text] [Related]
19. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1993 Apr; 69(4):375-80. PubMed ID: 8497850
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the thrombolytic efficacy of prourokinase by lys-plasminogen in a dog model of arterial thrombosis.
Badylak SF; Voytik SL; Henkin J; Burke SE; Sasahara AA; Simmons A
Thromb Res; 1991 May; 62(3):115-26. PubMed ID: 1716378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
